E. V. Puzakin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
E. V. Puzakin has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- A. A. Malov
Kazan State Medical University; Children’s Republican Clinical Hospital; Russian Medical Academy of Continuing Professional Education
1 shared publication - A. F. Yusupova
Kazan State Medical University
1 shared publication - A. V. Lokhova
P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre
1 shared publication - Aleksandr Igorevich Khalimon
Department of Nuclear Medicine, Moscow Oncology Research Institute, FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
1 shared publication - Aleksey Victorovich Leontyev
Department of Nuclear Medicine, P. Hertsen Moscow Oncology Research Institute - The Branch of the FSBI “National Medical Research Radiological Centre” of the Ministry of Health of the Russian Federation, Moscow, Russia
1 shared publication - Bulat M. Sharafutdinov
Russian Medical Academy of Postgraduate Education; Kazan State Medical Academy; Republican Clinical Oncological Dispansery named after Professor M.Z. Sigal
1 shared publication
Latest Publications
- Open Access
- 7 August 2023
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 104 (2) , 124-137
Radionuclide Diagnosis of Esophageal Dysmotility and Gastroesophageal Reflux in Patients with Systemic Sclerosis
Objective: to evaluate the possibilities of dynamic scintigraphy for the diagnosis of esophageal dysmotility (ED) and gastroesophageal reflux (GER) in patients with systemic sclerosis (SS).Material and methods. The study group included 77 patients with established SS of different disease duration (from several months to 30 years) who underwent Technephyt 99mTc dynamic esophageal scintigraphy using two-stage protocol. During the first stage, the esophageal transport function was evaluated; during the second stage, the presence and severity of GER were assessed. Scans were analyzed using visual assessment, quantitative estimation of time/activity curves, and a proposed three-point scale for evaluating ED and GER severity. The control group consisted of 19 practically healthy individuals who underwent a routine examination to exclude digestive system and gastrointestinal tract diseases, the algorithm of which included dynamic scintigraphy.Results. ED was found in 74 of 77 patients (96%). According to three-point scale, severe ED (3 points) was registrated in 41 (55%) patients, moderate ED (2 points) in 15 (21%), and mild ED in 18 (24%). GER was diagnosed in 35 of 77 cases (45%): mild GER in 13 (37%), moderate GER (2 points) in 22 (63%), and none of the patients was found to have severe GER (3 points). A significant relationship between the presence of GER and the severity of ED was not obtained, but a direct correlation was established between ED and GER severity.Conclusion. Most SS patients demonstrated ED of varying severity associated with mild and moderate GER in nearly 45% of the cases. The study results confirm the practical significance of dynamic scintigraphy for assessing the esophageal transport function and GER in SS patients.
- 7 August 2023
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 104 (2) , 124-137
Open AccessRadionuclide Diagnosis of Esophageal Dysmotility and Gastroesophageal Reflux in Patients with Systemic Sclerosis
Objective: to evaluate the possibilities of dynamic scintigraphy for the diagnosis of esophageal dysmotility (ED) and gastroesophageal reflux (GER) in patients with systemic sclerosis (SS).Material and methods. The study group included 77 patients with established SS of different disease duration (from several months to 30 years) who underwent Technephyt 99mTc dynamic esophageal scintigraphy using two-stage protocol. During the first stage, the esophageal transport function was evaluated; during the second stage, the presence and severity of GER were assessed. Scans were analyzed using visual assessment, quantitative estimation of time/activity curves, and a proposed three-point scale for evaluating ED and GER severity. The control group consisted of 19 practically healthy individuals who underwent a routine examination to exclude digestive system and gastrointestinal tract diseases, the algorithm of which included dynamic scintigraphy.Results. ED was found in 74 of 77 patients (96%). According to three-point scale, severe ED (3 points) was registrated in 41 (55%) patients, moderate ED (2 points) in 15 (21%), and mild ED in 18 (24%). GER was diagnosed in 35 of 77 cases (45%): mild GER in 13 (37%), moderate GER (2 points) in 22 (63%), and none of the patients was found to have severe GER (3 points). A significant relationship between the presence of GER and the severity of ED was not obtained, but a direct correlation was established between ED and GER severity.Conclusion. Most SS patients demonstrated ED of varying severity associated with mild and moderate GER in nearly 45% of the cases. The study results confirm the practical significance of dynamic scintigraphy for assessing the esophageal transport function and GER in SS patients.
- Open Access
- 14 April 2023
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 14 (1) , 63-72
Comparative assessment of 18F-PSMA-1007 biodistribution at 60 and 120 minutes after administration by PET/CT in prostate cancer patients
Сравнительная оценка биораспределения 18F-ПСМА-1007 через 60 и 120 минут после внутривенного введения при ПЭТ/КТ у пациентов, обследованных по поводу рака предстательной железы
- 14 April 2023
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 14 (1) , 63-72
Open AccessComparative assessment of 18F-PSMA-1007 biodistribution at 60 and 120 minutes after administration by PET/CT in prostate cancer patients
Сравнительная оценка биораспределения 18F-ПСМА-1007 через 60 и 120 минут после внутривенного введения при ПЭТ/КТ у пациентов, обследованных по поводу рака предстательной железы